The results of intravitreal ranibizumab injection for choroidal neovascularization from causes other thanage-related macular degeneration;Yaşa baǧli maküla dejeneresansi dişi nedenlerle gelişen koroid neovaskülarizasyonlarinda intravitreal ranibizumab enjeksiyonu sonuçlari

Retina-Vitreus

Volumn 19, Issue 4, 2011, Pages 231-236

  Gedik Oǧuz, Yeşim ^a   Batioǧlu, Figen ^a   Özmert, Emin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Angioid streaks; Best vitelliform dystrophy; Choroidal neovascularization; Degenerative myopia; Intravitreal ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ANGIOID STREAK; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE MYOPIA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD; MONOTHERAPY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA VITELLIFORM DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84856493948     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Gass JDM.: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, ed 4. St. Louis, Mosby. 1997.
2. K.B. Freund, L.A. Yannuzzi and J.A. Sorenson.: Age-related macular degeneration and choroidal neovascularization, Am J Ophthalmol. 1993; 115: 786-791. (Pubitemid 23171608)
3. Z. Cui, H. Kimura and C. Spee et al.: Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate, Graefes Arch Clin Exp Ophthalmol. 2000; 238: 326-333. (Pubitemid 30258927)
4. T. Ishibashi, Y. Hata and H. Yoshikawa et al.: Expression of vascular endothelial growth factor in experimental choroidal neovascularization, Graefes Arch Clin Exp Ophthalmol. 1997; 235: 159-167. (Pubitemid 27129479)
5. G. Martin, G. Schlunck, L.L. Hansen et al.: Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium, Graefes Arch Clin Exp Ophthalmol. 2004; 242: 321-326. (Pubitemid 38647606)
6. Eye Diseases Prevalence Research Group.: Prevalence of agerelated macular degeneration in the United States, Arch Ophthalmol. 2004; 122: 564-572.
7. Verteporfin in Photodynamic Therapy (VIP) Study Group.: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial VIP report no. 3, Ophthalmology. 2003; 110: 667-673.
8. Submacular Surgery Trials Research Group.: Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I: Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST report no. 9, Arch Ophthalmol. 2004; 122: 1597-1611.
9. Macular Photocoagulation Study Group.: Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials, Arch Ophthalmol. 1991; 109: 1109-1114.
10. Ferrara N, Damico L, Shams N et al.: Development of ranibizumab, an anti -vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26: 859-870. (Pubitemid 44547437)
11. Brown DM, Michels M, Kaiser PK, et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the anchor study. Ophthalmology. 2009; 116: 57-65.
12. Regillo CD, Brown DM, Abraham P et al.: Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008; 145: 239-248.
13. Rosenfeld PJ, Brown DM, Heier JS et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-1431. (Pubitemid 44511557)
14. Boyer DS, Heier JS, Brown DM et al.: A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116: 1731-1739.
15. Lalwani GA, Rosenfeld PJ, Fung AE et al.: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the pronto study. Am J Ophthalmol. 2009; 148: 43-58.
16. Bhatnagar P, Freund KB, Spaide RF et al.: Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina. 2007; 27: 897-902. (Pubitemid 47479384)
17. Rinaldi M, Dell'Omo R, Romano MR et al.: Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol. 2007; 125: 1422-1423. (Pubitemid 47606613)
18. Sawa M, Gomi F, Tsujikawa M et al.: Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol. 2009; 148: 584-590.
19. Wiegan TW, Rogers AH, McCabe F et al.: Intravitreal bevacizumab (avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br J Ophthalmol. 2009; 93: 47-51.
20. Chang LK, Spaide RF, Brue C et al.: Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol. 2008; 126: 941-945. (Pubitemid 352008374)
21. Neri P, Salvolini S, Mariotti C et al.: Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (avastin). Br J Ophthalmol. 2009; 93: 155-158.
22. Gomi F, Nishida K, Oshima Y et al.: Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol. 2007; 143: 507-510.
23. Inoue M, Kadonosono K, Watanabe Y et al.: Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Retina. 2010; 30: 733-738.
24. Vadala M, Pece A, Cipolla S et al.: Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab. Retina. 2010; 30: 903-907.
25. Lazaros K, Leonidas Z.: Intravitreal ranibizumab as primary treatment for neovascular membrane associated with angioid streaks. Acta Ophthalmol. 2010; 88: 100-101.
26. Konstantinidis L, Mantel I, Zografos L et al.: Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol 2010.
27. Silva RM, Ruiz-Moreno JM, Nascimento J et al.: Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina. 2008; 28: 1117-1123.
28. Silva RM, Ruiz-Moreno JM, Rosa P et al.: Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010; 30: 407-412.
29. Carnerio M, Silva M, Veludo J et al.: Ranibizumab treatment for choroidal neovascularization from causes other than Age-Related macular degeneration and pathological myopia, Ophthalmologica. 2011; 225: 81-88.
30. Torrón C, Egea C, Ferrer E et al.: Ranibizumab as treatment for myopic choroidal neovascularization. Arch Soc Esp Oftalmol. 2009; 84: 507-514.
31. Ruiz-Moreno JM, Montero JA, Amat-Peral P, et al.: Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol. 2011; 14.
32. Pece A, Avanza P, Galli L et al.: Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina. 1997; 17: 12-16. (Pubitemid 27091643)
33. Shyong MP, Chen SJ, Lee FL et al.: Increased and persisted subretinal haemorrhage after photodynamic therapy for choroidal neovascularization secondary to angioid streaks. Eye. 2006; 20: 1420-1422.
34. Jurklies B, Bornfeld N, Schilling H et al.: Photodynamic therapy using verteporfin for choroidal neovascularization associated with angioid streaks-long-term effects. Ophthalmic Res. 2006; 38: 209-217. (Pubitemid 44213981)
35. Gallego-Pinazo R., Dolz-Marco R., Pardo-López D. et al.: Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy Graefes Arch Clin Exp Ophthalmol. 2011; 249: 455-458.
36. Artunay O, Yuzbasioglu E, Rasier R et al.: Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: Preliminary clinical results of 12-month follow-up. Retina. 2011; 31: 1279-1286.